Literature DB >> 10773642

Posterior cerebral artery territory infarcts: clinical features, infarct topography, causes and outcome. Multicenter results and a review of the literature.

T Brandt1, W Steinke, A Thie, M S Pessin, L R Caplan.   

Abstract

Only a few large series of posterior cerebral artery (PCA) stroke exist, and clinical features and causes have not been studied as extensively as in other vascular territories. The PCA syndrome includes more clinical signs than the well-known visual field deficits. Concomitant findings are frequently sensory, slight motor and neuropsychological deficits. Unilateral headaches are the common presenting symptom making complicated migraine an important differential diagnosis. Combined deep and superficial PCA territory infarcts involving the lateral thalamus are more frequent than commonly assumed and are mostly associated with sensory and reversible slight motor deficits. Occlusion of the precommunal PCA segment with associated paramedian midbrain infarction causes severe motor deficits, oculomotor signs, and decreased consciousness and has a poorer outcome than other PCA territory infarcts. Embolism from a cardiac or undetermined source is the leading mechanism accounting for up to half of the cases, whereas arterial embolism from significant proximal vertebrobasilar disease is less frequent. Local atherothrombotic stenosis or occlusion of the PCA is uncommon. In spite of thorough diagnostic evaluation, the etiology of PCA territory infarction cannot be determined in at least one quarter of patients. Among the rare causes of PCA territory infarction carotid artery disease is important while the significance of migraine remains controversial. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2000        PMID: 10773642     DOI: 10.1159/000016053

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  18 in total

1.  Assessment of paramedian thalamic infarcts: MR imaging, clinical features and prognosis.

Authors:  Stefan Weidauer; Michael Nichtweiss; Friedhelm E Zanella; Heinrich Lanfermann
Journal:  Eur Radiol       Date:  2004-04-23       Impact factor: 5.315

2.  Subacute painless bilateral visual loss.

Authors:  Joseph Habboushe; Kamal Medlej; Kaushal Shah
Journal:  Intern Emerg Med       Date:  2010-04-21       Impact factor: 3.397

3.  Malignant posterior cerebral artery infarction.

Authors:  Th Pfefferkorn; A Deutschlaender; E Riedel; M Wiesmann; M Dichgans
Journal:  J Neurol       Date:  2006-12       Impact factor: 4.849

4.  The Posterior Cerebral Artery and its Main Cortical Branches Identified with Noninvasive Transcranial Color-Coded Duplex Sonography.

Authors:  P E Frid; S J Schreiber; O Pade; F Doepp; J Valdueza
Journal:  Ultrasound Int Open       Date:  2015-11-06

5.  14th EUNOS Congress: PORTO, PORTUGAL, 16-19 JUNE 2019.

Authors: 
Journal:  Neuroophthalmology       Date:  2019-06-07

Review 6.  [Value of modern CT-techniques in the diagnosis of acute stroke].

Authors:  P D Schellinger; J B Fiebach
Journal:  Radiologe       Date:  2004-04       Impact factor: 0.635

7.  Bilateral posterior cerebral artery infarction.

Authors:  Davinia Ryan; Sinead M Murphy; Michael J Hennessey
Journal:  BMJ Case Rep       Date:  2010-12-01

8.  Infarctions in the vascular territory of the posterior cerebral artery: clinical features in 232 patients.

Authors:  Adrià Arboix; Guillermo Arbe; Luis García-Eroles; Montserrat Oliveres; Olga Parra; Joan Massons
Journal:  BMC Res Notes       Date:  2011-09-07

9.  The hyperdense posterior cerebral artery sign in CT is related to larger ischemic lesion volume.

Authors:  Wojciech Ambrosius; Varsha Gupta; Radoslaw Kazmierski; Agnieszka Hellmann; Guoyu Qian; Wieslaw L Nowinski
Journal:  Pol J Radiol       Date:  2011-04

10.  Factors delaying intravenous thrombolytic therapy in acute ischaemic stroke: a systematic review of the literature.

Authors:  Angelos Sharobeam; Brett Jones; Dianne Walton-Sonda; Christian J Lueck
Journal:  J Neurol       Date:  2020-03-21       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.